1084.8000 -35.20 (-3.14%)
NSE Oct 01, 2026 15:31 PM
Volume: 340.8K
 

1084.80
-3.14%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. is trading below its 30 day SMA of 1115.5
More from Strides Pharma Science Ltd.
Recommended